AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05977491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Health care practitioner is informed about POCT result for TV and BV
Description: The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
Study NCT05977491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: addressing psycholsocial problems
Description: 1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics
Study NCT06365476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused extracorporeal shock wave therapy (ESWT)
Description: The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
Study NCT06313021 — intervention group
Intervention type: OTHER
Intervention: Reliability and Validity Study
Description: Reliability and Validity Study
Study NCT06365476 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: focused extracorporeal shock wave therapy (ESWT)
Description: The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
Study NCT05546801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnaire on postnatal development
Study NCT05096169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 25mg
Description: clomiphene citrate at a dose of 25mg daily
Study NCT05096169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: clomiphene citrate at a dose of 50mg every other day
Study NCT06494176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neVR Fear the Dentist
Description: neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
Study NCT04781660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Alginate Hydrogel
Description: Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart.
Study NCT06036147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concussion-focused cognitive behavioral therapy
Description: Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
Study NCT04981704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib Tablets
Study NCT04981704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Oral solution
Study NCT04981704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin Capsules
Study NCT04981704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine Tablets
Study NCT05119504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment
Description: During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
Study NCT05119504 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Multi-Health Behavior
Description: The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
Study NCT06036147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent skills training
Description: The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
Study NCT04731662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sleep
Description: 6-hours time-in-bed during weeknights
Study NCT06036147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Description: In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
Study NCT04731662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable short sleep
Description: Variable hours of time-in bed during weeknights
Study NCT05503732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
Study NCT05503732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Drink
Description: Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
Study NCT06349473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR604
Description: SR604 will be administered as SC injection.
Study NCT06349473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as single SC injection.
Study NCT05623085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
Study NCT05623085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercise
Description: Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
Study NCT06118281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
Study NCT06118281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
Study NCT06067659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
Study NCT06067659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
Study NCT05362175 — intervention group
Intervention type: DEVICE
Intervention: Obstetric ultrasound
Description: ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
Study NCT05072041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexsphere™
Description: Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
Study NCT06184503 — intervention group
Intervention type: DRUG
Intervention: Velmanase Alfa
Description: Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
Study NCT05487495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR T (CT125B)
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
Study NCT04895280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
Study NCT04895280 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Marcaine
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
Study NCT04895280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
Study NCT04895280 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kenalog
Description: Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
Study NCT06067659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy+Kinesiology taping
Description: Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
Study NCT03274375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA session
Description: 10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
Study NCT03274375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)
Study NCT04593160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium- acetaminophen combination
Description: Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
Study NCT04593160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Preoperative single dose of diclofenac potassium(50mg)
Study NCT04593160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative single dose of placebo
Study NCT06222047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk
Description: give breast milk before the OG catheter insertion
Study NCT06222047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dextrose
Description: give %20 dextrose before the OG catheter insertion
Study NCT06137547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypotension prediction index (HPI)
Description: The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
Study NCT06324578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AT Testing
Description: Analysis of blood specimens and neck ultrasonography
Study NCT05302232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: depomedrone 40mg/ml + 1% lidocaine
Description: Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
Study NCT05302232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: depomedrone 40mg/ml+ 0.9% saline
Description: Response to intra-articular injection of steroid only as a placebo
Study NCT05302232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: painDETECT questionnaire
Description: painDETECT questionnaire
Study NCT05302232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: painDETECT questionnaire
Description: painDETECT questionnaire
Study NCT04662632 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System with Tobramycin Sulfate
Description: Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
Study NCT04662632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
Study NCT04662632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
Study NCT01021163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine, saline
Description: Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
Study NCT06430255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: Program for treatment
Study NCT06430255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-guided Supervised Exercise
Description: Program for treatment
Study NCT05571150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad-focused strategy training intervention
Description: The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to.
Study NCT05571150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control intervention
Description: The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
Study NCT04662632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
Study NCT04662632 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System with Vancomycin Hydrochloride
Description: Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
Study NCT05890586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Study NCT05890586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT02545127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merotocin
Description: Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study NCT06514651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAQ-001
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
Study NCT02545127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study NCT05376553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg intravenous infusion over 30 minutes